Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
Tanguy Y. Seiwert(Georgetown University), Laura Q.M. Chow(The University of Texas at Austin), Shilpa Gupta(Cleveland Clinic), Francis P. Worden(Georgetown University), Barbara Burtness(Yale University), Andrea L. Webber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen V. Liu(Georgetown University), Ranee Mehra(University of Maryland, Baltimore), Joseph P. Eder(Yale Cancer Center), Lingkang Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joshua Bauml(University of Pennsylvania), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyunseok Kang(Johns Hopkins University), Robin Mogg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert I. Haddad(Georgetown University), Jared Weiss(Georgetown University), Iris Gluck(Sheba Medical Center), David G. Pfister(Memorial Sloan Kettering Cancer Center), Jonathan D. Cheng(Princeton University), Makoto Tahara(National Cancer Center Hospital East)
Cited by 38
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k